Technical Analysis for CORI - Corium International, Inc.
|Grade||Last Price||% Change||Price Change|
CORI closed down 0.94 percent on Friday, May 25, 2018, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical CORI trend table...|
|Date||Alert Name||Type||% Chg|
|May 25||NR7||Range Contraction||0.00%|
|May 25||Lower Bollinger Band Walk||Weakness||0.00%|
|May 25||Inside Day||Range Contraction||0.00%|
|May 25||Oversold Stochastic||Weakness||0.00%|
|May 24||Slingshot Bearish||Bearish Swing Setup||-0.94%|
|May 24||Bullish Engulfing||Bullish||-0.94%|
|May 24||Lower Bollinger Band Walk||Weakness||-0.94%|
|May 24||Lower Bollinger Band Touch||Weakness||-0.94%|
|May 24||Oversold Stochastic||Weakness||-0.94%|
|May 23||Calm After Storm||Range Contraction||2.80%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Corium International, Inc., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of specialty pharmaceutical products. Its products include Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for management of chronic pain, including cancer-related pain; Crest Whitestrips, a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company is also developing AG200-15, a combination hormonal contraceptive patch in Phase III clinical trials that delivers ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system, which has completed Phase I clinical trials for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed Phase I clinical trials for the treatment of benign prostatic hyperplasia. In addition, its products that have completed development, scale-up, and clinical activities include motion sickness patch for the prevention of nausea and vomiting associated with motion sickness; and urology patch for treatment of a urologic condition. Further, the company is developing Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company, Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc., and Agile Therapeutics, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CORI news...
|52 Week High||13.93|
|52 Week Low||6.77|
|200-Day Moving Average||10.657|
|50-Day Moving Average||10.1658|
|20-Day Moving Average||9.2465|
|10-Day Moving Average||8.827|
|Average True Range||0.4937|
|Chandelier Exit (Long, 3 ATRs )||8.7689|
|Chandelier Exit (Short, 3 ATRs )||9.5811|
|Upper Bollinger Band||10.3913|
|Lower Bollinger Band||8.1017|
|Percent B (%b)||0.14|
|MACD Signal Line||-0.4742|
|Market Cap||301.3 Million|
|Num Shares||35.7 Million|
|Price-to-Earnings (P/E) Ratio||-4.90|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||8.82|
|Resistance 3 (R3)||8.82||8.70||8.76|
|Resistance 2 (R2)||8.70||8.60||8.70||8.73|
|Resistance 1 (R1)||8.56||8.54||8.50||8.56||8.71|
|Support 1 (S1)||8.30||8.34||8.24||8.30||8.15|
|Support 2 (S2)||8.18||8.28||8.18||8.13|
|Support 3 (S3)||8.04||8.18||8.11|
|Support 4 (S4)||8.04|